Skinvisible (SKVI) EBITDA Margin (QoQ) (2010 - 2026)
Powered by 
Analysis
Skinvisible (SKVI) EBITDA Margin (QoQ) (2010 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 663.08 Bn | 642.33 Bn | 17.26 Bn |
| 2 | AbbVie | 453.04 Bn | 446.51 Bn | 12.70 Bn |
| 3 | Merck | 370.87 Bn | 363.78 Bn | 12.21 Bn |
| 4 | Novartis Ag | 305.29 Bn | 298.00 Bn | 11.24 Bn |
| 5 | Pfizer | 162.10 Bn | 150.70 Bn | 10.94 Bn |
| 6 | Sanofi | 53.95 Bn | 46.98 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 45.00 Bn | 45.00 Bn | - |
| 8 | Incyte | 25.47 Bn | 20.94 Bn | 1.57 Bn |
| 9 | United Therapeutics | 20.81 Bn | 18.15 Bn | 683.80 Mn |
| 10 | Skinvisible | 1.08 Mn | 1.08 Mn | 5,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 26,242.00 |
| Mar 31, 2026 | -23,538.00 |
| Dec 31, 2025 | -16,224.00 |
| Sep 30, 2025 | 60,360.00 |
| Jun 30, 2025 | 7,230.00 |
| Mar 31, 2025 | 117,782.00 |
| Dec 31, 2024 | -147,548.00 |
| Sep 30, 2024 | 35,448.00 |
| Jun 30, 2024 | -39,018.00 |
| Mar 31, 2024 | 26,708.00 |
| Dec 31, 2023 | -46,856.00 |
| Sep 30, 2023 | -574.00 |
| Jun 30, 2023 | 30,162.00 |
| Mar 31, 2023 | -20,376.00 |
| Dec 31, 2022 | -98,928.00 |
| Sep 30, 2022 | -140,698.00 |
| Jun 30, 2022 | 17,456.00 |
| Mar 31, 2022 | -19,096.00 |
| Dec 31, 2021 | 6,540.00 |
| Sep 30, 2021 | -6,261.00 |